Press release content from PR Newswire. The AP news staff was not involved in its creation.
Alternative meat venture Next Meats broadcasts Japan’s first alternative meat brand television commercial, just 10 months after establishment
April 2, 2021 GMT
Logo (PRNewsfoto/Next Meats Co., Ltd.)
TOKYO, April 1, 2021 /PRNewswire/ The Tokyo based food-tech venture Next Meats, established last year in June, announced they will be airing a television commercial on several channels in Japan starting April, which will make it the first time an alternative meat brand will air a commercial on public television in the country.
Next Meats explains that in order to effectively tackle the climate crisis issue and mitigate its effects, great speed and execution is required in all parts of business which led to the release of their commercial only 10 months after establishment. They noted that their commercial which has three language variations will be played in other countries as well.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Moderna Provides Storage Update & Announces the U.S. FDA Authorizes Up To 15-Doses Per Vial of its COVID-19 Vaccine
April 2, 2021 GMT
CAMBRIDGE, Mass. (BUSINESS WIRE) Apr 1, 2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that based on submitted stability data, the U.S. Food and Drug Administration (FDA) has authorized the Moderna COVID-19 Vaccine to be kept at room temperature conditions once removed from the refrigerator for administration for 24 hours, an increase from the previous 12 hours. Additionally, a punctured vial is now useable for up to 12 hours, an increase from the previous 6 hours. These new guidelines are reflected in an updated Emergency Use Authorization (EUA) label. The Moderna COVID-19 Vaccine is ready for use and does not need to be diluted.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Chindata Group Releases 2020 Environmental, Social and Governance (ESG) Report
April 2, 2021 GMT
BEIJING, April 2, 2021 /PRNewswire/ Chindata Group (Nasdaq: CD), a leading carrier-neutral hyperscale data center solution provider in Asia-Pacific emerging markets, has released its second annual Environmental, Social and Governance (ESG) Report today, which highlights the company’s 2020 ESG results towards its 2030 carbon-neutrality goal and digital-inclusiveness vision.
With the theme of “Inspiring with Power”, the Report includes a detailed roadmap for carbon neutrality, demonstrating Chindata Group’s sustainability and digital prosperity values. In December 2020, Chindata Group announced that all its hyperscale data centers in China would source 100 percent renewable energy and invest in clean energy with an installed capacity of no less than 2GW by 2030.
Press release content from Business Wire. The AP news staff was not involved in its creation.
2021 Home Care in China Market Outlook - Positive Outlook for Laundry Sanitiser Category - ResearchAndMarkets.com
April 2, 2021 GMT
The “Home Care in China” report has been added to ResearchAndMarkets.com’s offering.
The COVID-19 crisis had a marked influence on the performance of home care in the Chinese market in 2020. Overall volumes saw stronger growth than in the previous year, as the pandemic led to increased consumer concerns about hygiene and long periods of home confinement resulted in more engagement in a wide range of household tasks.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Adalimumab: Sold Under the Brand Name Humira - Global Biosimilar Insight Report 2021 - ResearchAndMarkets.com
April 2, 2021 GMT
The “Adalimumab - Biosimilar Insight, 2021” report has been added to ResearchAndMarkets.com’s offering.
This “Adalimumab - Biosimilar Insight, 2021,” report provides comprehensive insights about 34+ companies and 35+ marketed and pipeline drugs in Adalimumab Biosimilars landscape.
ADVERTISEMENT
It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.